Souhaitez-vous accéder aux communiqués récents ?

-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- --...

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior...

RiskLayer, developed by Chainrisk Labs, has secured its Builders Round, co-led by Antler and Momentum6. This round includes investors like Wagmi Ventures,

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...

-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...

-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a...

-- CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients -- -- Next ANTLER update planned for H2 2023 -- BERKELEY,...

-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong...